We are live on ! Find out more
CYTO

Altamira Therapeutics Ltd

Delisted

CYTO was delisted on the 19th of December, 2024.

5 hedge funds and large institutions have $47.3K invested in Altamira Therapeutics Ltd in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

551% more capital invested

Capital invested by funds: $7.26K → $47.3K (+$40K)

17% less funds holding

Funds holding: 65 (-1)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
5
Holders Change
-1
Holders Change %
-16.67%
% of All Funds
0.08%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
Reduced
1
Closed
3
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Citadel Advisors
1
Citadel Advisors
Florida
$46.7K +$71.9K +3,647 New
Morgan Stanley
2
Morgan Stanley
New York
$321 -$513 -26 -51%
Group One Trading
3
Group One Trading
Illinois
$191 +$296 +15 New
Wells Fargo
4
Wells Fargo
California
$16
SCA
5
Stonebridge Capital Advisors
Minnesota
$3
Citigroup
6
Citigroup
New York
-$3.94K -154 Closed
UBS Group
7
UBS Group
Switzerland
-$1.96K -77 Closed
Osaic Holdings
8
Osaic Holdings
Arizona
-$19 -1 Closed

CYTO Hedge Fund Activity: Q2 2023 in Review

5 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Altamira Therapeutics Ltd (CYTO) for Q2 2023, worth a combined $47.3K — up 551% from $7.26K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of CYTO and 2 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $71.9K. The largest seller was Citigroup, exiting entirely with an estimated $3.94K sold.

  • 5 institutional investors held Altamira Therapeutics Ltd (CYTO) as of Q2 2023, down from 6 in Q1 2023.
  • Funds reported $47.3K of Altamira Therapeutics Ltd stock for Q2 2023, up 551% quarter-over-quarter.
  • 2 funds opened new Altamira Therapeutics Ltd positions in Q2 2023 and 3 closed out, a net change of -1 holder.
  • The largest Altamira Therapeutics Ltd buyer in Q2 2023 was Citadel Advisors, an estimated $71.9K added.
  • The largest Altamira Therapeutics Ltd seller in Q2 2023 was Citigroup, an estimated $3.94K sold.

Based on aggregated 13F filings for Q2 2023.